KAMADA LTD
KMDA · Pharmaceutical Preparations · EDGAR filings ↗
Grade
B81gen composite 75pct→81
Notable findings
- Customer concentration~50% of revenue from one customer/distributor — ” We expect that KEDRAB, GLASSIA and CYTOGAM, which combined accounted for approximately 50% of our revenues and approximately 70% of our gross profitability in the year ended December 31, 2025, wil
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Gross margin
42.3%
Operating margin
14.5%
Net margin
11.2%
Return on equity
7.5%
Return on assets
5.3%
ROIC
7.7%
Revenue growth (QoQ)
14.5%
Net-income growth
39.7%
Interest coverage
30.4×
Current ratio
4.1×
EBITDA
$28M
Tangible book value
$239M
Cash & investments
$75M
Leadership & compensation
| Name | Role | Latest total comp |
|---|---|---|
| London Amir | Chief Executive Officer | — |
| Beladev Shavit | VP Plasma Operations | — |
| Brenner Yael | VP Quality | — |
| Gorelik Boris | VP, BD and Strategic Programs | — |
| Livneh Nir | VP, General Counsel | — |
| Neheman Hanni | VP, Marketing & Sales | — |
| Nir Eran | VP, Operations | — |
| ORLEV CHAIME | Chief Financial Officer | — |
| Pinchuk Orit | VP Regulatory Affairs | — |
| Reshef Liron | VP Human Resources | — |
| DAVIDI ISHAY | Director | — |
| Dekel Benjamin | Director | — |
| Goldwasser Karnit | Director | — |
| ITSHAYEK ASSAF | Director | — |
| Payorski Lilach | Director | — |
| RECANATI LEON | Director | — |
| Tsur David | Director | — |
Officers & directors from SEC filings (Form 4 + DEF 14A proxy); compensation is the latest reported fiscal year.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT04204252 ↗ | Phase III, Efficacy and Safety of "Kamada-AAT for Inhalation" Alpha 1-Antitrypsin Deficiency | PHASE3 | Recruiting | 2028-12-01 |
| NCT06958796 ↗ | Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV) Cytomegalovirus, Organ Transplant | PHASE4 | Recruiting | 2027-12-30 |
| NCT07009548 ↗ | CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients Cytomegalovirus (CMV) Infection | PHASE4 | Enrolling By Invitation | 2027-12-01 |
| NCT04550325 ↗ | Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19 Covid19, Pneumonia, Viral | PHASE1/PHASE2 | Completed | 2020-11-26 |
| NCT02912845 ↗ | Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to Rabies Rabies | PHASE3 | Completed | 2019-11-13 |
| NCT02614872 ↗ | Study to Evaluate the Safety and Efficacy of Intravenous Glassia® Treatment in Lung Transplantation Transplantation, Lung Rejection | PHASE2 | Completed | 2019-04-11 |
| NCT02956122 ↗ | A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD Graft Versus Host Disease | PHASE2/PHASE3 | Terminated | 2018-05-03 |
| NCT02005848 ↗ | Phase II Study to Evaluate the Efficacy and Safety of Glassia® in Type-1 Diabetes New Onset Type-1 Diabetes | PHASE2 | Completed | 2017-02-01 |
| NCT01661192 ↗ | Long Term Treatment Effect of the Safety, Tolerability and Efficacy of AAT in Type 1 Diabetes Type 1 Diabetes, Beta Cell Preservation | PHASE2 | Completed | 2017-01-01 |
| NCT02001688 ↗ | Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation" Alpha-1 Antitrypsin Deficiency | PHASE2 | Completed | 2016-02-01 |
| NCT01217671 ↗ | International Study Evaluating the Safety and Efficacy of Inhaled, Human, Alpha-1 Antitrypsin (AAT) in Alpha-1 Antitrypsin Deficient Patients With Emphysema Emphysema | PHASE2/PHASE3 | Completed | 2014-11-01 |
| NCT02040090 ↗ | Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy Subjects Rabies | PHASE2/PHASE3 | Completed | 2014-08-01 |
| NCT01304537 ↗ | Study of the Safety and Efficacy of Intravenous Alpha-1 Antitrypsin in Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus | PHASE1/PHASE2 | Completed | 2012-11-01 |
| NCT00499837 ↗ | Phase II Study of the Safety and Efficacy of Inhaled Alpha-1 Antitrypsin (AAT ) in Cystic Fibrosis Patients Cystic Fibrosis | PHASE2 | Completed | 2008-07-01 |
| NCT00460096 ↗ | Phase II/III Study of an Alpha-1 Proteinase Inhibitor (Kamada-API) in Individuals With Alpha-1 Antitrypsin Deficiency Alpha 1-Antitrypsin Deficiency | PHASE2/PHASE3 | Completed | |
| NCT03172455 ↗ | Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) Acute-graft-versus-host Disease, Steroid Refractory Acute Graft Versus Host Disease | — | No Longer Available |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 20-F | 2026-03-11 | 2025-12-31 | 0001213900-26-025934 ↗ |
| 20-F | 2025-03-05 | 2024-12-31 | 0001213900-25-020360 ↗ |
| 20-F | 2024-03-06 | 2023-12-31 | 0001213900-24-020272 ↗ |
| 20-F | 2023-03-15 | 2022-12-31 | 0001213900-23-020114 ↗ |
| 20-F | 2022-03-15 | 2021-12-31 | 0001213900-22-012308 ↗ |
| 20-F | 2021-02-24 | 2020-12-31 | 0001213900-21-011255 ↗ |
| 20-F | 2020-02-26 | 2019-12-31 | 0001213900-20-004782 ↗ |
| 20-F | 2019-02-27 | 2018-12-31 | 0001178913-19-000698 ↗ |
| 20-F | 2018-03-06 | 2017-12-31 | 0001178913-18-000767 ↗ |
| 20-F | 2017-03-01 | 2016-12-31 | 0001178913-17-000668 ↗ |
| 20-F | 2016-02-25 | 2015-12-31 | 0001178913-16-004529 ↗ |
| 20-F | 2015-04-28 | 2014-12-31 | 0001178913-15-001343 ↗ |